 Intercept Pharmaceuticals Inc. on Monday released additional results of a closely watched clinical trial suggesting that an experimental liver-disease drug may have had a more benign effect on patients' cholesterol levels than initially thought. . The new study details—which Intercept disclosed in a securities filing and on a conference call with analysts—sparked a nearly 60% surge in Intercept's stock price in after-hours trading Monday, to $378.50, after closing at $237.18. Analysts believe the drug has multi-billion-dollar...
  